Ventilator-Associated Pneumonia

Ventilator-associated pneumonia occurs in patients who have been intubated for at least 2–3 days with significant exposure to hospital-acquired organisms. Treatment should be initiated rapidly and cover Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, and methicillin-resistant Staphyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Maley, Jason H., Stevens, Jennifer P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120513/
http://dx.doi.org/10.1007/978-3-030-26710-0_29
_version_ 1783514989179437056
author Maley, Jason H.
Stevens, Jennifer P.
author_facet Maley, Jason H.
Stevens, Jennifer P.
author_sort Maley, Jason H.
collection PubMed
description Ventilator-associated pneumonia occurs in patients who have been intubated for at least 2–3 days with significant exposure to hospital-acquired organisms. Treatment should be initiated rapidly and cover Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, and methicillin-resistant Staphylococcus aureus(MRSA). Within 72 h or with the availability of culture results, antibiotics should be narrowed. Active research is on-going to identify patients at risk for ventilator-associated complications and to minimize the likelihood of infection in these patients.
format Online
Article
Text
id pubmed-7120513
institution National Center for Biotechnology Information
language English
publishDate 2019
record_format MEDLINE/PubMed
spelling pubmed-71205132020-04-06 Ventilator-Associated Pneumonia Maley, Jason H. Stevens, Jennifer P. Evidence-Based Critical Care Article Ventilator-associated pneumonia occurs in patients who have been intubated for at least 2–3 days with significant exposure to hospital-acquired organisms. Treatment should be initiated rapidly and cover Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumonia, and methicillin-resistant Staphylococcus aureus(MRSA). Within 72 h or with the availability of culture results, antibiotics should be narrowed. Active research is on-going to identify patients at risk for ventilator-associated complications and to minimize the likelihood of infection in these patients. 2019-07-24 /pmc/articles/PMC7120513/ http://dx.doi.org/10.1007/978-3-030-26710-0_29 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Maley, Jason H.
Stevens, Jennifer P.
Ventilator-Associated Pneumonia
title Ventilator-Associated Pneumonia
title_full Ventilator-Associated Pneumonia
title_fullStr Ventilator-Associated Pneumonia
title_full_unstemmed Ventilator-Associated Pneumonia
title_short Ventilator-Associated Pneumonia
title_sort ventilator-associated pneumonia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120513/
http://dx.doi.org/10.1007/978-3-030-26710-0_29
work_keys_str_mv AT maleyjasonh ventilatorassociatedpneumonia
AT stevensjenniferp ventilatorassociatedpneumonia

Ejemplares similares